サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：尿路感染症（UTI）治療の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1192932

尿路感染症（UTI）治療の世界市場－成長、将来展望、競合分析（2022年～2030年）

Urinary Tract Infection (UTI) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
尿路感染症（UTI）治療の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月17日
発行: Acute Market Reports
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の尿路感染症（UTI）治療市場について調査分析し、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の尿路感染症（UTI）治療市場
  • 世界の尿路感染症（UTI）治療市場（100万米ドル）（2021年）：薬剤クラス別
  • 世界の尿路感染症（UTI）治療市場（100万米ドル）（2021年）：地域別
  • 魅力的な投資提案（2021年）：地域別

第3章 尿路感染症（UTI）治療市場：競合分析

  • 主要な尿路感染症（UTI）治療市場ベンダーの市場ポジショニング
  • 尿路感染症（UTI）治療市場のベンダーが採用する戦略
  • 主要な業界戦略
  • 階層分析：2021年と2030年の比較

第4章 尿路感染症（UTI）治療市場：マクロ分析と市場力学

  • イントロダクション
  • 世界の尿路感染症（UTI）治療市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 尿路感染症（UTI）治療市場、米ドル（100万）（2020年～2030年）：薬剤クラス別

  • 市場概要
  • 成長と収益分析：：2021年と2030年の比較
  • 市場セグメンテーション
    • ペニシリン
    • キノロン
    • セファロスポリン
    • スルホンアミド
    • テトラサイクリン
    • その他

第6章 北米の尿路感染症（UTI）治療市場、米ドル（100万）（2020年～2030年）

第7章 英国および欧州連合の尿路感染症（UTI）治療市場、米ドル（100万）（2020年～2030年）

第8章 アジア太平洋の尿路感染症（UTI）治療市場、米ドル（100万）（2020年～2030年）

第9章 ラテンアメリカの尿路感染症（UTI）治療市場、米ドル（100万）（2020年～2030年）

第10章 中東およびアフリカの尿路感染症（UTI）治療市場、米ドル（100万）（2020年～2030年）

第11章 企業プロファイル

  • AstraZeneca plc.
  • Bayer AG
  • Cubist Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Johnson & Johnson
  • MerLion Pharmaceuticals
  • Osel Inc.
  • Pfizer Inc.
  • Rempex Pharmaceuticals
図表

List of Tables

  • TABLE 1 Global Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 2 North America Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 3 U.S. Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 4 Canada Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 5 Rest of North America Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 7 UK Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 8 Germany Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 9 Spain Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 10 Italy Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 11 France Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 12 Rest of Europe Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 13 Asia Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 14 China Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 15 Japan Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 16 India Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 17 Australia Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 18 South Korea Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 19 Latin America Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 20 Brazil Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 21 Mexico Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 22 Rest of Latin America Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 24 GCC Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 25 Africa Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)
  • TABLE 26 Rest of Middle East and Africa Urinary Tract Infection (UTI) Treatment Market By Drug Class, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Urinary Tract Infection (UTI) Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Urinary Tract Infection (UTI) Treatment Market: Quality Assurance
  • FIG. 5 Global Urinary Tract Infection (UTI) Treatment Market, By Drug Class, 2021
  • FIG. 6 Global Urinary Tract Infection (UTI) Treatment Market, By Geography, 2021
  • FIG. 7 Market Geographical Opportunity Matrix - Global Urinary Tract Infection (UTI) Treatment Market, 2021
  • FIG. 8 Market Positioning of Key Urinary Tract Infection (UTI) Treatment Market Players, 2021
  • FIG. 9 Global Urinary Tract Infection (UTI) Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
  • FIG. 10 Global Urinary Tract Infection (UTI) Treatment Market, By Drug Class, 2021 Vs 2030, %
  • FIG. 11 U.S. Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Canada Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 Rest of North America Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 UK Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Germany Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Spain Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 Italy Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 France Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 Rest of Europe Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 China Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 Japan Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 India Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 Australia Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 South Korea Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Asia Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Brazil Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Mexico Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Latin America Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 GCC Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Africa Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
  • FIG. 31 Rest of Middle East and Africa Urinary Tract Infection (UTI) Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 137750-08-22

Urinary tract infection (UTI) is a most common type of infection, it involve infection to the kidneys, ureters, bladder, or urethra. UTI treatment market is rapidly growing due to factors such as growing prevalence of UTI, significant unmet needs, rising number of drug resistant bacteria due to excessive use of antibiotics.

The report titled "Urinary Tract Infection (UTI) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall UTI treatment market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on drug class (penicillin, quinolones, cephalosporin, sulphonamides, tetracycline and other) and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global UTI treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global UTI treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global UTI treatment market. In-depth competitive environment analysis and historical years (2021) market size data are also provided in the report.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Urinary Tract Infection (UTI) Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Urinary Tract Infection (UTI) Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Penicillin

Quinolones

Cephalosporin

Sulphonamides

Tetracycline

Other

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Urinary Tract Infection (UTI) Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Urinary Tract Infection (UTI) Treatment market?

Which is the largest regional market for Urinary Tract Infection (UTI) Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Urinary Tract Infection (UTI) Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Urinary Tract Infection (UTI) Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Urinary Tract Infection (UTI) Treatment Market
  • 2.2. Global Urinary Tract Infection (UTI) Treatment Market, By Drug Class, 2021 (US$ Million)
  • 2.3. Global Urinary Tract Infection (UTI) Treatment Market, By Geography, 2021 (US$ Million)
  • 2.4. Attractive Investment Proposition by Geography, 2021

3. Urinary Tract Infection (UTI) Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Urinary Tract Infection (UTI) Treatment Market Vendors
  • 3.2. Strategies Adopted by Urinary Tract Infection (UTI) Treatment Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2021 Versus 2030

4. Urinary Tract Infection (UTI) Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Urinary Tract Infection (UTI) Treatment Market Value, 2020 - 2030, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Penicillin
    • 5.3.2. Quinolones
    • 5.3.3. Cephalosporin
    • 5.3.4. Sulphonamides
    • 5.3.5. Tetracycline
    • 5.3.6. Other

6. North America Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 6.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.North America
      • 6.3.1.1. U.S.
        • 6.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.2. Canada
        • 6.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 6.3.1.3. Rest of North America
        • 6.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)

7. UK and European Union Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 7.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.UK and European Union
      • 7.3.1.1. UK
        • 7.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.2. Germany
        • 7.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.3. Spain
        • 7.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.4. Italy
        • 7.3.1.4.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.5. France
        • 7.3.1.5.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 7.3.1.6. Rest of Europe
        • 7.3.1.6.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)

8. Asia Pacific Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 8.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Asia Pacific
      • 8.3.1.1. China
        • 8.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.2. Japan
        • 8.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.3. India
        • 8.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.4. Australia
        • 8.3.1.4.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.5. South Korea
        • 8.3.1.5.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 8.3.1.6. Rest of Asia Pacific
        • 8.3.1.6.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)

9. Latin America Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 9.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Latin America
      • 9.3.1.1. Brazil
        • 9.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.2. Mexico
        • 9.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 9.3.1.3. Rest of Latin America
        • 9.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)

10. Middle East and Africa Urinary Tract Infection (UTI) Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
  • 10.3.Urinary Tract Infection (UTI) Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.3.1.Middle East and Africa
      • 10.3.1.1. GCC
        • 10.3.1.1.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.2. Africa
        • 10.3.1.2.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)
      • 10.3.1.3. Rest of Middle East and Africa
        • 10.3.1.3.1. Urinary Tract Infection (UTI) Treatment Market: By Drug Class, 2020-2030, USD (Million)

11. Company Profile

  • 11.1. AstraZeneca plc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bayer AG
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Cubist Pharmaceuticals
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. F. Hoffmann-La Roche Ltd.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. GlaxoSmithKline Pharmaceuticals Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Johnson & Johnson
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. MerLion Pharmaceuticals
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Osel Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Pfizer Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Rempex Pharmaceuticals
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives